Cardinal Health price target lowered to $240 from $260 at BofA

BofA lowered the firm’s price target on Cardinal Health (CAH) to $240 from $260 to reflect lower peer multiples, while keeping a Buy rating on the shares. The firm notes Cardinal Health reported a mixed-to-positive Q3 and raised FY26 EPS guidance, driven by below the line items and continued strength in the Pharma/Other segments. The guidance raise should also alleviate investor concerns around a potential moderation in industry growth, BofA argues.